Clinicopathological features, treatment and survival outcomes of synovial sarcoma
Introduction: Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological treatment parameters and survival outcomes of SS patients. Materials and Methods: A total of 57...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2018-01-01
|
| Series: | South Asian Journal of Cancer |
| Subjects: | |
| Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=270;epage=272;aulast=Kuruva |
| _version_ | 1824018815219924992 |
|---|---|
| author | Siva Prasad Kuruva Stalin Bala Meher Lakshmi Konatam Ashok Kumar Karnam Lakshmi Srinivas Maddali Sadashuivudu Gundeti |
| author_facet | Siva Prasad Kuruva Stalin Bala Meher Lakshmi Konatam Ashok Kumar Karnam Lakshmi Srinivas Maddali Sadashuivudu Gundeti |
| author_sort | Siva Prasad Kuruva |
| collection | DOAJ |
| description | Introduction: Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological treatment parameters and survival outcomes of SS patients. Materials and Methods: A total of 57 histologically proven SS diagnosed from 2010 to 2016 were retrospectively analyzed. Results: The median age was 23 years with a male-to-female ratio of 1.28:1. Localized disease was seen in 44 patients (77%) and 13 patients (23%) had metastasis. The primary sites of involvement such as lower limb, upper limb, thorax, and abdomen were seen in 60%, 28%, 7%, and 5% patients, respectively. Surgery was done in 39 patients and 18 patients had unresectable disease. Adjuvant chemotherapy with doxorubicin-based regimen was given in 30 patients and adjuvant radiotherapy in 21 patients. Palliative chemotherapy with anthracycline-based or gemcitabine-based regimen was used in 17 and 2 patients, respectively. The median event-free survival (EFS) was 30 months with 3 years and EFS rate was 36%; median progression-free survival (PFS) was 11.5 months and 1 year; and PFS rate was 38%. On univariate analysis, resection and performance status were significantly associated with survival. There is no impact of grade and size of the tumor on survival. In metastatic patients, the lung is the most common site. Conclusion: SS is the most common soft-tissue sarcoma among adults. Resectability and performance status were impacting the survival. |
| first_indexed | 2024-12-19T01:11:04Z |
| format | Article |
| id | doaj.art-1422b77a3b5946bfb3b5334c7d1ae5ce |
| institution | Directory Open Access Journal |
| issn | 2278-330X |
| language | English |
| last_indexed | 2024-12-19T01:11:04Z |
| publishDate | 2018-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | South Asian Journal of Cancer |
| spelling | doaj.art-1422b77a3b5946bfb3b5334c7d1ae5ce2022-12-21T20:42:58ZengThieme Medical and Scientific Publishers Pvt. Ltd.South Asian Journal of Cancer2278-330X2018-01-017427027210.4103/sajc.sajc_269_17Clinicopathological features, treatment and survival outcomes of synovial sarcomaSiva Prasad KuruvaStalin BalaMeher Lakshmi KonatamAshok Kumar KarnamLakshmi Srinivas MaddaliSadashuivudu GundetiIntroduction: Synovial sarcoma (SS) is a malignant mesenchymal tumor. It is most common among children and adults. The data on SS from India are scarce. In this study, we analyzed the clinicopathological treatment parameters and survival outcomes of SS patients. Materials and Methods: A total of 57 histologically proven SS diagnosed from 2010 to 2016 were retrospectively analyzed. Results: The median age was 23 years with a male-to-female ratio of 1.28:1. Localized disease was seen in 44 patients (77%) and 13 patients (23%) had metastasis. The primary sites of involvement such as lower limb, upper limb, thorax, and abdomen were seen in 60%, 28%, 7%, and 5% patients, respectively. Surgery was done in 39 patients and 18 patients had unresectable disease. Adjuvant chemotherapy with doxorubicin-based regimen was given in 30 patients and adjuvant radiotherapy in 21 patients. Palliative chemotherapy with anthracycline-based or gemcitabine-based regimen was used in 17 and 2 patients, respectively. The median event-free survival (EFS) was 30 months with 3 years and EFS rate was 36%; median progression-free survival (PFS) was 11.5 months and 1 year; and PFS rate was 38%. On univariate analysis, resection and performance status were significantly associated with survival. There is no impact of grade and size of the tumor on survival. In metastatic patients, the lung is the most common site. Conclusion: SS is the most common soft-tissue sarcoma among adults. Resectability and performance status were impacting the survival.http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=270;epage=272;aulast=KuruvaClinicopathologicalsurvivalsynovial sarcomatreatment |
| spellingShingle | Siva Prasad Kuruva Stalin Bala Meher Lakshmi Konatam Ashok Kumar Karnam Lakshmi Srinivas Maddali Sadashuivudu Gundeti Clinicopathological features, treatment and survival outcomes of synovial sarcoma South Asian Journal of Cancer Clinicopathological survival synovial sarcoma treatment |
| title | Clinicopathological features, treatment and survival outcomes of synovial sarcoma |
| title_full | Clinicopathological features, treatment and survival outcomes of synovial sarcoma |
| title_fullStr | Clinicopathological features, treatment and survival outcomes of synovial sarcoma |
| title_full_unstemmed | Clinicopathological features, treatment and survival outcomes of synovial sarcoma |
| title_short | Clinicopathological features, treatment and survival outcomes of synovial sarcoma |
| title_sort | clinicopathological features treatment and survival outcomes of synovial sarcoma |
| topic | Clinicopathological survival synovial sarcoma treatment |
| url | http://journal.sajc.org/article.asp?issn=2278-330X;year=2018;volume=7;issue=4;spage=270;epage=272;aulast=Kuruva |
| work_keys_str_mv | AT sivaprasadkuruva clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma AT stalinbala clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma AT meherlakshmikonatam clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma AT ashokkumarkarnam clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma AT lakshmisrinivasmaddali clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma AT sadashuivudugundeti clinicopathologicalfeaturestreatmentandsurvivaloutcomesofsynovialsarcoma |